Therapy Area topics
Cardiovascular
New US nod widens the net for Entresto
Entresto can now be used in five million of six million US heart failure patients, but Novartis admits ramp-up in the new population will be slow.
Central Nervous System
A busy year ahead for Parkinson’s disease
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
Digital Health
Onduo takes its time
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
Philips spends nearly $3bn to integrate Biotelemetry
The deal is a late entrant into 2020's top five mergers and acquisitions.
Prescription apps take off during lockdown
Digital therapeutics are going from strength to strength during the pandemic.
Oncology
Five Prime's lesson in never giving up
The group’s restructuring, C-suite clearout and refocusing on bemarituzumab is rewarded with a $1.9bn buyout by Amgen.
Inovio’s reinvention falls flat
The company’s claims of a win with its cervical precancer therapy candidate look questionable.
Respiratory
Kinaset takes a sledgehammer to an asthma conundrum
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Various
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
